TOMIOKA SATORU, KUBO EIJI, KOBAYASHI KANA, ARAI SHIGEYUKI, TAMURA YOSHIFURU, KURIBAYASHI EMIKO, CHANG WENXIU, UCHIDA Erlotinib in vitro SHUNYA Department of Internal Medicine, Faculty of Medicine, Teikyo University, Tokyo, Japan Introduction: When to start hemdialysis remains a matter of debate. Too early or too late is neither optimal. Serum creatinine (Cr) is the only numerical indicator for the

start of hemodialysis decided by the committee of the Ministry of Health, Labour and Welfare of Japan. In this study, the appropriate start point for hemodialysis was investigated not only by serum Cr but also by other parameters including patients’ symptoms. Methods: Out of the 333 patients started on hemodialysis in our hospital between 2001 and 2006, we selected patients who received outpatient treatment for more than six months and whose serum Cr trends were linearly regressive. Patients with increased serum CRP were excluded. Finally, 78 patients were enrolled in the analysis. First, the two sets of data were prepared; one was the data at the start of hemodialysis and another date was one month previously. Logistic regression analysis was applied to reveal predictors. Results: In all cases, serum Cr was extracted as the most influencial predictor followed by serum sodium (Na) and serum β2 microglobulin (β2MG) for judging the

start point for hemodialysis. The discriminating ability by these three factors increased to 75% from 66% by serum Cr alone. In the sex-based analysis, only serum PS-341 mw Cr was significant in male while the serum

Na and β2MG levels were significant when serum Cr was excluded in female. Conclusion: Serum Cr is an appropriate parameter when to start hemodialysis. In addition, serum β2MG and serum Na are also influencial of factors especially in female. The optimal start point of hemodialysis may be determined by concidering multiple predictors rather than serum Cr alone, leading to more appropriate judgment. ARDHANY ARDITYO RAHMAT1,2,3, THAHA MOCHAMMAD1,2, YOGIANTORO MOHAMMAD1, YASUHIKO TOMINO3 1Nephrology and Hypertension Division, Department of Internal Medicine Faculty of Medicine Airlangga University, Dr. Soetomo Teaching Hospital Surabaya, Indonesia; 2Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia; 3Division of Nephrology, Juntendo School of Medicine, Tokyo, Japan Introduction: The prevalence of hyperhomocysteinaemia in hemodialysis patients reaches 90–95%. Hyperhomocysteinaemia increased cardiovascular risk. Various therapies by supraphysiologic dose of folic acid, vitamin B6, and B12 failed to normalize the homocysteine level, especially in hemodialysis patients. Oral dose of 1200 mg N-Acetylcysteine (NAC) has been shown to reduce plasma level of homocysteine. However, its effect in the form of capsule has not been investigated. Capsule dosage form is expected to reduce the strong smell of NAC and gastritis experienced by patients who take the effervescent tablet.